Interpace Biosciences, Inc.
6.47
USD
+0.02
(+0.31%)
CIK
1054102
ISIN
US46062X4025
CUSIP
46062X402
Return %
Stock
S&P 500
1Y
-68.45
14.20
3Y
-77.50
81.12
5Y
-97.12
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Thomas W. Burnell
- Full Time Employees
- 102
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Parsippany United States
- CIK
- 0001054102
- Website
- interpace.com
- Similar Companies
- Business
- Interpace Biosciences, Inc. is a commercial-stage molecular diagnostics company that develops and commercializes specialized genomic tests and pathology services to support the early diagnosis, risk stratification, and clinical management of cancer. The company specializes in evaluating indeterminate biopsies to guide personalized patient treatment decisions and avoid unnecessary surgical procedures. The company offers a proprietary molecular testing portfolio and clinical laboratory services, which include: ThyGeNEXT, an expanded next-generation sequencing oncogenic mutation panel that identifies DNA mutations and RNA fusions across genes associated with thyroid malignancies; ThyraMIR and ThyraMIR v2, proprietary microRNA gene expression classifiers that measure expression levels of diagnostic microRNAs to assess the malignant potential of indeterminate thyroid nodules; and integrated co-testing solutions, which algorithmically pair mutational profiling with microRNA expression analysis to classify fine-needle aspiration biopsy samples into low, moderate, or high risk for malignancy. Interpace Biosciences processes diagnostic specimens through its high-complexity, CLIA-certified and College of American Pathologists-accredited clinical reference laboratory located in Pittsburgh, Pennsylvania, serving endocrinologists, endocrine surgeons, community hospitals, academic medical centers, multi-specialty physician networks, and pathology practices across the United States. In recent strategic developments, Interpace Biosciences has restructured its operations to transition into a pure-play, specialized thyroid diagnostics company. The company completed the divestiture of its biopharma-facing Interpace Pharma Solutions business unit to Flagship Biosciences, Inc., followed by the formal discontinuation of its legacy PancraGEN pancreatic diagnostic testing line. In 2026, the company eliminated its preferred equity obligations and simplified its capital structure through the conversion of all outstanding Series C preferred stock into common stock. Furthermore, Interpace Biosciences implemented a 1-for-5 reverse stock split of its common stock in August 2026 as part of its strategic initiative to pursue an uplisting to the Nasdaq Stock Market. Founded in 1986 and formerly known as PDI, Inc. and Interpace Diagnostics Group, Inc., Interpace Biosciences, Inc. is headquartered in Parsippany, New Jersey, and conducts its primary commercial and laboratory activities through its wholly owned operating subsidiary, Interpace Diagnostics, LLC.